A three-drug combination extends lifespan in aged mice while simultaneously targeting senescent and cancer cells

A new experimental approach targets two fundamental problems of ageing at the same time

A new preclinical study is attracting attention in longevity research after scientists tested a combination of dichloroacetate (DCA), metformin and low-dose navitoclax designed to exploit metabolic vulnerabilities shared by senescent and cancer cells. The strategy is particularly interesting because it attempts to address two processes that become increasingly important with age: the accumulation of senescent cells — damaged or stressed cells that stop dividing but remain metabolically active — and the growing risk of cancer. In laboratory experiments, the three-drug combination produced stronger effects than the individual components alone, while experiments in aged mice reported improvements in physical-performance measures and an increase in survival after treatment began. In one experiment, treated animals showed an average extension of approximately 102.6 days from the beginning of treatment, equivalent to around 41.7% of the post-intervention period. The result is striking, but it needs to be interpreted with considerable caution: extending the remaining lifespan of already-aged mice after an intervention begins is not the same as extending total lifespan by 41.7%, and nothing in these experiments demonstrates that the same treatment would extend human life.

The scientific interest lies in the logic behind the combination. Ageing is not driven by a single biological mechanism. It involves interconnected processes including cellular senescence, mitochondrial dysfunction, chronic inflammation, altered nutrient sensing, genomic instability, epigenetic changes and declining regenerative capacity. Cancer simultaneously becomes more common with age because mutations accumulate and the biological environment surrounding cells changes. A therapy capable of selectively affecting dysfunctional cells while preserving healthy tissue could therefore have implications extending beyond a single age-related disease. This is one of the central ambitions of modern geroscience: rather than treating cardiovascular disease, cancer, frailty, neurodegeneration and metabolic disease as entirely independent problems, researchers increasingly ask whether some of their underlying biological drivers can be targeted directly.

Senescent cells have become one of the most closely watched targets in longevity science

Cellular senescence originally evolved as a protective mechanism. When a cell experiences substantial damage or stress, stopping division can prevent it from becoming malignant. The problem emerges when senescent cells accumulate in tissues and fail to be efficiently removed by the immune system. These cells can release inflammatory molecules, growth factors and other signalling compounds — collectively described as the senescence-associated secretory phenotype, or SASP — that can alter surrounding tissue and contribute to chronic inflammation.

This has created an entire field of research around senolytics, compounds designed to selectively eliminate senescent cells, and senomorphics, which attempt to modify their harmful behaviour without necessarily destroying them. Navitoclax is one of the compounds investigated in senolytic research because it inhibits proteins within the BCL-2 family that some senescent cells depend on for survival. However, navitoclax also presents important safety concerns, including effects on platelets, which is one reason why approaches using lower doses or combinations are scientifically interesting.

The commercial implications are considerable. If cellular senescence eventually becomes a validated therapeutic target in humans, the potential market would not necessarily be limited to one disease. Senescent cells have been investigated in relation to fibrosis, osteoarthritis, cardiovascular disease, metabolic dysfunction, pulmonary disease, neurodegeneration and other age-associated conditions. A successful intervention could therefore potentially sit at the intersection of multiple therapeutic categories.

But this possibility remains an area of research rather than established clinical medicine. Results in cells and mice cannot be extrapolated directly to people.

Metformin brings one of the most studied drugs in ageing research into the combination

The second component, metformin, is one of the world’s most widely used medicines for type 2 diabetes and has become a recurring subject in longevity research. Its appeal comes partly from epidemiological observations and its effects on pathways related to glucose metabolism, mitochondrial function, insulin signalling and cellular energy sensing. Researchers have consequently investigated whether metformin might influence biological processes associated with ageing beyond its established role in diabetes.

Metformin is particularly interesting because longevity medicine increasingly focuses on metabolic health as a fundamental component of healthspan. Insulin resistance, obesity, chronic inflammation and cardiovascular risk can interact throughout adulthood and influence the probability of developing multiple diseases later in life. A drug that modifies metabolic pathways could therefore theoretically influence more than one age-associated outcome.

However, metformin should not be described as a proven anti-ageing drug. Its established medical use is primarily for diabetes and related indications, and whether it can meaningfully extend lifespan or healthspan in healthy humans remains unresolved. This distinction is essential because enthusiasm surrounding longevity can easily transform an interesting research hypothesis into an unsupported consumer claim.

Dichloroacetate targets another metabolic vulnerability

Dichloroacetate, or DCA, adds another layer to the strategy because it influences cellular energy metabolism, particularly the balance between glycolysis and mitochondrial oxidation. Cancer cells frequently exhibit altered metabolism, and senescent cells can also develop distinctive metabolic characteristics. The researchers’ rationale is therefore to combine metabolic pressure with mechanisms that make dysfunctional cells more vulnerable to elimination.

The broader scientific idea is important. Instead of searching for one “longevity molecule”, researchers can combine agents that attack different biological vulnerabilities simultaneously. This resembles strategies already used successfully in areas such as oncology and infectious disease, where combination therapy can be more effective than relying on a single mechanism.

For longevity research, combination therapy could eventually become particularly relevant because ageing itself is multifactorial. If ten or more biological processes deteriorate simultaneously, expecting one compound to reverse the entire phenotype may be unrealistic.

The experiment in aged mice is particularly interesting because treatment began late in life

One of the most attractive aspects of the study is the use of already-aged animals. Many lifespan experiments begin interventions relatively early, which can make translation to humans difficult. Most people will not begin a longevity therapy at the biological equivalent of adolescence. The commercially and medically relevant question is whether interventions can produce benefits when started during later life.

The reported experiments included mice approximately 18 to 24 months old, an advanced age for laboratory mice. Researchers observed improvements in selected physical-performance tests and reported increased survival in one experimental setting after treatment began. The average extension of approximately 102.6 days is noteworthy precisely because it occurred after intervention in older animals.

But this figure requires careful communication. Saying that the therapy “extended lifespan by 41.7%” without qualification could be misleading. The percentage refers to the survival period measured after the intervention began under the reported experimental conditions, not to a 41.7% increase in the animals’ entire lifespan from birth.

That distinction is essential when translating laboratory findings into public communication.

The simultaneous relationship with cancer makes the approach particularly intriguing

One of the fundamental difficulties of longevity biology is that mechanisms promoting tissue regeneration can sometimes increase cancer risk. Encouraging cells to proliferate or suppressing protective mechanisms without sufficient control can theoretically create conditions favourable to tumour formation. Conversely, mechanisms such as cellular senescence can protect against cancer early in life while becoming detrimental when senescent cells accumulate later.

This biological tension explains why a strategy attempting to address both senescent and malignant cells is particularly interesting. A successful longevity intervention cannot simply make cells younger or more proliferative; it must preserve mechanisms protecting the organism from cancer.

The relationship between ageing and cancer is therefore likely to become one of the most important areas of geroscience. As populations live longer, cancer incidence rises partly because there has been more time for mutations and cellular damage to accumulate. Any intervention intended for long-term use in otherwise healthy older adults will require an exceptionally strong safety profile.

From treating diseases individually to targeting the biology that connects them

This study belongs to a much larger transformation in medicine. Conventional healthcare is organised primarily around individual diseases. Cardiologists treat cardiovascular disease, oncologists treat cancer, neurologists treat neurodegeneration and endocrinologists manage metabolic disorders. Geroscience asks a different question: what if several of these conditions share upstream mechanisms associated with biological ageing?

If ageing biology can be modified safely, one intervention could theoretically influence the risk or progression of several conditions simultaneously. This concept is sometimes described as targeting the hallmarks of ageing, including cellular senescence, mitochondrial dysfunction, genomic instability, epigenetic alteration, loss of proteostasis, altered nutrient sensing, stem-cell exhaustion and chronic inflammation.

The economic implications would be enormous. Pharmaceutical development is traditionally structured around one medicine, one indication and one defined patient population. Longevity therapeutics could eventually challenge that architecture if regulators accept interventions aimed at biological processes associated with multiple age-related outcomes.

That is a very large “if”. Ageing itself is not generally treated as a conventional disease indication by major regulators, and demonstrating clinical benefit would require clearly defined endpoints.

The real prize is healthspan rather than simply lifespan

Another important distinction is between lifespan and healthspan. Extending life without preserving physical and cognitive function would have limited value for individuals and could increase healthcare and dependency costs. The objective of serious longevity research is therefore increasingly focused on extending the period of life spent in good health.

The physical-performance improvements reported in the mice are interesting for precisely this reason. Researchers and regulators will eventually need to know not simply whether an intervention increases survival, but whether treated organisms remain stronger, more mobile, cognitively functional and less affected by disease.

In humans, future longevity trials may therefore require combinations of endpoints: muscle strength, walking speed, cognition, immune function, metabolic health, incidence of major diseases and mortality. This makes longevity trials complex and expensive, but it also creates an enormous market for biomarkers, clinical-trial infrastructure, digital monitoring and longitudinal health data.

Artificial intelligence could accelerate the search for longevity combinations

The number of possible drug combinations is enormous. If researchers want to test existing drugs, experimental molecules, supplements and biological therapies across multiple ageing pathways, traditional trial-and-error approaches quickly become impractical. Artificial intelligence can help identify combinations that may act synergistically by analysing molecular networks, gene expression, protein interactions and existing pharmacological data.

This creates another convergence between longevity biotechnology and AI. The future may involve computational models identifying candidate combinations, organoids and animal models validating them, and adaptive clinical trials testing the most promising approaches in humans.

Digital twins could eventually simulate how different biological profiles might respond to different interventions, although this remains an emerging field rather than established clinical practice.

The companies that control high-quality longitudinal datasets could therefore become extremely valuable. Developing longevity therapies requires understanding not simply whether a biomarker changes today, but how biological systems evolve over years.

Drug repurposing could become one of the fastest routes into longevity therapeutics

Another commercially interesting characteristic of this combination is that its components are not entirely new molecules created specifically for ageing. Metformin has decades of clinical use, DCA has been studied in several medical contexts and navitoclax has been investigated extensively in oncology.

This creates opportunities for drug repurposing: identifying new applications for existing pharmacological compounds. Repurposing can sometimes provide more existing information about pharmacokinetics, toxicity and biological activity than starting with a completely new molecule, although every new indication still requires rigorous clinical validation.

Artificial intelligence is making repurposing increasingly attractive because algorithms can analyse enormous quantities of biomedical literature and molecular information to identify unexpected relationships between drugs and ageing mechanisms.

The longevity pharmaceutical industry may therefore develop through two parallel routes: entirely new therapies specifically designed around ageing biology and combinations or repurposed compounds originally developed for other diseases.

Human translation remains the enormous unanswered question

This is where enthusiasm must be tempered. Biology is full of interventions that extend lifespan in worms, flies or mice but fail to produce comparable effects in humans. Mice have much shorter lifespans, different metabolism, different disease patterns and highly controlled environments. Laboratory animals also tend to be genetically more homogeneous than human populations.

A human longevity intervention must operate safely for potentially many years in people who may not initially be ill. The tolerance for serious adverse effects is therefore much lower than in oncology, where patients may accept substantial toxicity because they face life-threatening disease.

Navitoclax illustrates the problem particularly well because its known effects on platelets may limit its suitability for widespread preventive use. Using lower doses or combinations may potentially alter that balance, but only human clinical trials can establish whether an acceptable therapeutic window exists.

For now, there is no evidence that this three-drug combination extends human lifespan.

No one should use these findings as justification for self-medication.

The Longevity Economy could eventually create an entirely new pharmaceutical category

Despite those limitations, the direction of research is strategically important. If interventions targeting cellular senescence, metabolism and other hallmarks of ageing eventually demonstrate clinical benefit, a new pharmaceutical category could emerge between preventive medicine and conventional disease treatment.

The potential customer would not necessarily be a patient with advanced disease. It could eventually be a 60- or 70-year-old with an elevated biological risk profile who wants to reduce the probability of multiple age-related conditions.

That would fundamentally change the addressable market.

Instead of treating one disease after diagnosis, longevity therapeutics would attempt to modify biological risk before several diseases emerge.

Pharmaceutical companies, insurers, healthcare systems and regulators would then face entirely new questions: Who qualifies for treatment? Which biomarkers define biological ageing? How long should treatment continue? What endpoints demonstrate efficacy? Who pays? How should long-term adverse effects be monitored?

These questions will determine whether geroscience becomes a major medical industry or remains primarily a research field.

The study matters less for the three specific drugs than for the strategy it represents

The greatest importance of the research may ultimately not lie in DCA, metformin or navitoclax themselves. Future studies may find that the combination is unsuitable for humans, requires different dosing or should be replaced by safer compounds.

What matters is the strategy: target multiple mechanisms of ageing simultaneously while attempting to control cancer risk.

That is a much more sophisticated objective than searching for a mythical anti-ageing pill.

Ageing is a network problem. The future of longevity medicine may therefore require network solutions: combinations of pharmacology, nutrition, exercise, regenerative medicine, diagnostics and artificial intelligence tailored to the biological characteristics of each individual.

The three-drug experiment in aged mice is one small piece of that much larger scientific transformation.

It does not prove that humans can live longer by taking these medicines.

But it strengthens a question that could eventually reshape medicine:

What happens if, instead of waiting for individual diseases of ageing to appear, we intervene earlier in the biological processes that help produce them?

If science eventually answers that question successfully in humans, the impact will extend far beyond healthcare.

It could create an entirely new industry around extending healthy human life.

Prepare to lead the longevity economy

Geroscience, biotechnology, senolytics, artificial intelligence and preventive medicine are opening entirely new markets around the biology of ageing. The MBA in Longevity Business by FIFTIERS prepares executives, entrepreneurs and investors to understand these emerging industries, identify opportunities and develop business models for the rapidly expanding global Longevity Economy.